Results 1 to 10 of about 10,858,974 (235)
Some of the next articles are maybe not open access.
Annals of Surgical Oncology, 2021
9563 Background: Talimogene Laherparepvec (T-VEC) is a genetically modified herpes simplex type 1 virus and known as an effective oncolytic immunotherapy for injectable cutaneous, subcutaneous, and nodal melanoma lesions in stage IIIB-IVM1a patients. Recently, Stahlie et al.
Emma H. A. Stahlie +3 more
openaire +2 more sources
9563 Background: Talimogene Laherparepvec (T-VEC) is a genetically modified herpes simplex type 1 virus and known as an effective oncolytic immunotherapy for injectable cutaneous, subcutaneous, and nodal melanoma lesions in stage IIIB-IVM1a patients. Recently, Stahlie et al.
Emma H. A. Stahlie +3 more
openaire +2 more sources
Journal of Clinical Oncology, 2018
e21545Background: A recent trial comparing T-vec+Ipi vs Ipi found no differential benefit in progression-free survival (PFS) (HR 0.83, 95%CI 0.56–1.23), but noted objective response rates (ORR) of ...
Abdulaali Almutairi +5 more
openaire +1 more source
e21545Background: A recent trial comparing T-vec+Ipi vs Ipi found no differential benefit in progression-free survival (PFS) (HR 0.83, 95%CI 0.56–1.23), but noted objective response rates (ORR) of ...
Abdulaali Almutairi +5 more
openaire +1 more source
Talimogene laherparepvec (T-VEC) as a treatment for melanoma: A systematic review
Journal of Oncology Pharmacy PracticeBackground and aims Melanoma now presents an average risk of 1 in 50 in the Western world. Talimogene laherparepvec (T-VEC), an FDAapproved oncolytic virus derived from Herpes Simplex Virus type 1 (HSV-1), has proven effective in reducing morbidity and mortality from melanoma but causes adverse effects like ...
Sai Santhosha Mrudula Alla +10 more
openaire +2 more sources
American Journal of Clinical Dermatology, 2020
Talimogene laherparepvec (T-VEC) is the first agent approved for cancer in the emerging class of oncolytic viral therapies. While T-VEC was approved for the treatment of advanced melanoma in 2015, clinical utilization has been hampered by rapid changes in the therapeutic landscape of melanoma related to advances in both immune checkpoint blockade and ...
Cecilia A. Larocca +3 more
openaire +2 more sources
Talimogene laherparepvec (T-VEC) is the first agent approved for cancer in the emerging class of oncolytic viral therapies. While T-VEC was approved for the treatment of advanced melanoma in 2015, clinical utilization has been hampered by rapid changes in the therapeutic landscape of melanoma related to advances in both immune checkpoint blockade and ...
Cecilia A. Larocca +3 more
openaire +2 more sources
Journal of Immunotherapy, 2020
In the era of immunotherapy for cancer, solid organ transplant patients who go on to develop metastatic or locally advanced melanoma offer particularly difficult challenges. New approaches are needed for these patients. We present a case of in-transit metastatic melanoma in a renal transplant patient.
Joel C, Sunshine +3 more
openaire +2 more sources
In the era of immunotherapy for cancer, solid organ transplant patients who go on to develop metastatic or locally advanced melanoma offer particularly difficult challenges. New approaches are needed for these patients. We present a case of in-transit metastatic melanoma in a renal transplant patient.
Joel C, Sunshine +3 more
openaire +2 more sources
Journal of Clinical Oncology, 2018
11516Background: T-VEC is an oncolytic immunotherapy derived from HSV type-1 that is modified to selectively replicate within tumors and produce GM-CSF.
Ciara Marie Kelly +18 more
openaire +1 more source
11516Background: T-VEC is an oncolytic immunotherapy derived from HSV type-1 that is modified to selectively replicate within tumors and produce GM-CSF.
Ciara Marie Kelly +18 more
openaire +1 more source
ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC
Annals of Surgical Oncology, 2022Emma H. A. Stahlie +1 more
openaire +2 more sources
Exanthem nach einmaliger Injektion von T‐VEC
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2019Daniel, Wagenknecht +3 more
openaire +2 more sources
Rash after a single injection of T‐VEC
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2019Daniel Wagenknecht +3 more
openaire +1 more source
Fortgeschrittenes Melanom: zusätzliche Gabe von T-VEC ohne Nutzen
hautnah dermatologie, 2023openaire +1 more source

